News
ProKidney Corp. (PROK) shares just saw a massive green day. Results from Phase 2 were compelling and the data sharply ...
US clinical-stage biotech ProKidney reported statistically-significant and clinically-meaningful positive top-line results ...
The company also encounters competitive risks from other organizations developing therapies for chronic kidney disease.
ProKidney shares surged 500% on positive Phase 2 CKD results. Read why I remain cautious about PROK stock despite the recent ...
16h
Zacks.com on MSNPROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy StudyShares of ProKidney Corp. PROK skyrocketed 515% yesterday after the company reported encouraging top-line data from the phase ...
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company ...
ProKidney shares are trading sharply higher Wednesday morning. The stock is gaining following a marked surge on Tuesday ...
Over the last 7 days, the United States market has remained flat, though it is up 13% over the past year with an optimistic forecast for earnings growth. In such a landscape, identifying stocks with ...
21h
InvestorsHub on MSNProKidney Shares Soar After Citi Lifts Price Target to $9Shares of ProKidney Corp. (NASDAQ:PROK) jumped 65% in pre-market trading Wednesday, extending the dramatic rally seen on ...
WK Kellogg shares jumped 50.2% to $26.31 in the pre-market trading session. Here are some other stocks moving in pre-market ...
Researchers at the Chinese Academy of Sciences and collaborators have developed a new method to label and monitor dormant breast cancer cells over time, shedding light on how these cells survive ...
In the second largest M&A deal of the year, Merck & Co. Inc. has strengthened its cardiopulmonary portfolio with the $10 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results